https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency
EMA’s human medicines committee (CHMP) recommended 15 medicines for approval at its December 2020 meeting.
Spain-Instuctions for conducting clinical trials in Spain (version 13)_30Nov2020
https://www.ema.europa.eu/en/about-us/brexit-uk-withdrawal-eu/brexit-related-guidance-companies
From 1 January 2021, the following legal obligations will apply to holders of UK marketing authorisations (MA).
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-november-2020
Denmark-New European legislation on the way for clinical trials_03Nov2020
EMA’s human medicines committee (CHMP) recommended five medicines for approval at its November 2020 meeting.
EMA and the national competent authorities (NCAs) in EU Member States have prepared a safety monitoring plan for COVID-19 vaccines.
